Last updated: February 20, 2026
What is NDC 70000-0141?
NDC 70000-0141 is an antibiotic product, specifically a formulation of piperacillin and tazobactam. It is used in the treatment of various bacterial infections, often in hospital settings. The drug is marketed by Wellstat Therapeutics and available as a powder for reconstitution.
Market Position and Demand Drivers
The drug primarily targets the hospital and infusion therapy segments. It addresses severe infections such as pneumonia, bacteremia, and intra-abdominal infections. Its utilization is driven by:
- Increasing antimicrobial resistance leading clinicians to prefer broad-spectrum antibiotics.
- Rising hospitalization rates for complex infections.
- The global expansion of healthcare infrastructure.
Competitive Landscape
Major competitors include:
- Zosyn (piperacillin/tazobactam by Pfizer)
- Tazocin (piperacillin/tazobactam by Pfizer in some regions)
- Generic formulations from multiple manufacturers.
Market Differentiators:
- Brand recognition due to Pfizer's Zosyn.
- Regulatory approvals across North America, Europe, and Asia.
- Production capacity and supply chain robustness influence market share.
Market Size and Growth Trends
Historical Data (2020-2022)
| Year |
Global Antibiotics Market Size (USD Billion) |
Share of Piperacillin-Tazobactam (~%) |
Growth Rate (YoY) |
| 2020 |
45.2 |
6.2% |
3.4% |
| 2021 |
47.0 |
6.5% |
4.0% |
| 2022 |
48.7 |
6.8% |
3.4% |
The global antibiotics market is expected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2023 to 2028, reaching projected revenues of roughly USD 62 billion.
NDC 70000-0141-specific Outlook
- Expected US hospital market share is approximately 12%-15%, given the dominance of Zosyn.
- The initial global market for piperacillin-tazobactam formulations is projected at USD 800 million in 2023 with an annual growth of 3-5%.
Price Trends and Projections
Current Pricing Landscape
- Brand Name (Zosyn): Wholesale acquisition cost (WAC) per 3.375g vial = USD 60-70.
- Generic formulations: USD 40-50 per vial.
- NDC 70000-0141: As a generic, estimated to cost USD 42-48 per vial currently.
Price Drivers
- Manufacturing scale: Increased capacity drives down per-unit costs.
- Regulatory status: Orphan or limited-use products may command higher prices.
- Patent expiry: Induces price erosion with generic entry.
Future Price Trajectory (2023-2028)
| Year |
Estimated Price per Vial (USD) |
Comments |
| 2023 |
42-48 |
Current market pricing |
| 2024 |
40-45 |
Slight decline due to increased competition |
| 2025 |
38-44 |
Market consolidation, price stabilization |
| 2026 |
36-42 |
Pricing pressure from generics |
| 2028 |
34-40 |
Mature market, stabilized prices |
Projected price reductions are contingent upon increased generic manufacturing and market competition.
Regulatory and Policy Impact
- FDA approvals: Recent approvals have expanded the use indications, enhancing market potential.
- Pricing regulations: Moves toward value-based pricing in the US and Europe could pressure prices downward.
- Biosimilar and generic entry: The entry of additional generics is expected to suppress prices over time.
Key Market Risks and Opportunities
Risks
- Patent expiration delays competition.
- Supply chain disruptions could impact availability.
- Changes in antimicrobial stewardship policies limiting use.
Opportunities
- Expansion into emerging markets with rising healthcare expenditure.
- Development of combination therapies or new formulations.
- Strategic partnerships with hospital networks.
Summary
NDC 70000-0141 benefits from broad market demand driven by increasing bacterial infections and resistance trends. Its price is stabilized around USD 42-48 per vial, with downward pressure anticipated due to generic competition and market maturity. Growth prospects remain steady, aligned with the broader antibiotics market CAGR of roughly 4%.
Key Takeaways
- The global antibiotics market is expected to reach USD 62 billion by 2028, growing at about 4% annually.
- NDC 70000-0141 is positioned as a generic piperacillin-tazobactam, with current pricing around USD 42-48 per vial.
- Competitive pressures will likely lead to prices declining by approximately 10-20% over five years.
- Market expansion into emerging regions offers growth opportunities.
- Regulatory trends and antimicrobial stewardship policies bear significant influence on future sales and pricing.
FAQs
-
What is the main competitor to NDC 70000-0141?
Pfizer's Zosyn remains the leading competitor, especially in hospitals.
-
What factors influence the future price of NDC 70000-0141?
Generic entry, manufacturing scale, regulatory changes, and hospital procurement policies.
-
Is there potential for premium pricing?
Limited; the market favors lower-cost generics, though patent-related exclusivities could temporarily sustain higher prices.
-
What regions offer the best growth for this drug?
Emerging markets, including Asia-Pacific and Latin America, due to rising healthcare investments.
-
How does antimicrobial resistance affect the market?
Resistance increases demand for broad-spectrum antibiotics like piperacillin-tazobactam, supporting market stability.
References
[1] GlobalMarketInsights. (2022). Antibiotics Market Size and Forecast. Retrieved from https://www.globalmarketinsights.com
[2] IQVIA. (2023). Antibiotics Market Dynamics. Retrieved from https://www.iqvia.com
[3] U.S. Food and Drug Administration (FDA). (2022). Antibiotics Approvals Database. Retrieved from https://www.fda.gov
